MTM(688029)2024-10-31 09:28Financial Performance - In Q3 2024, the company achieved a revenue of 679 million CNY, a 13.4% increase from 598 million CNY in the same period last year [2] - The gross profit margin for Q3 2024 was approximately 67.1%, up by 2.3 percentage points year-on-year [2] - Net profit for Q3 2024 reached 141 million CNY, a 15.1% increase from 122 million CNY in the previous year [2] - For the first three quarters of 2024, total revenue was 2.012 billion CNY, a 15.3% increase from 1.745 billion CNY in the same period last year [2] Market Performance - Revenue from the Asia-Pacific market was about 338 million CNY, showing slight growth, while domestic revenue slightly declined due to centralized procurement impacts [2] - The Americas market generated 144 million CNY, with a year-on-year growth of 19.2%, and the U.S. local business grew by 33% [2] - The EMEA market revenue was 124 million CNY, reflecting a 36.5% increase [2] Research and Development - R&D expenses for Q3 2024 were approximately 42 million CNY, a 23.8% increase year-on-year, accounting for about 6.2% of sales revenue [2] - The company is focusing on high-potential core projects, including innovative products in the pipeline [5] Strategic Responses - The company is adapting to challenges from domestic centralized procurement by reducing inventory and adjusting product structures [3] - Plans to enhance overseas market presence include increasing investment in Europe, Japan, and Australia, alongside channel acquisitions [5] - The company aims to maintain a strong growth trajectory in international sales, expecting that by 2025, international sales will surpass domestic sales [5] Future Outlook - The company is optimistic about the domestic market, anticipating significant growth potential compared to developed countries [5] - Continuous innovation and product launches are planned to counteract price declines and stabilize market performance [5] - The company is committed to improving patient outcomes and achieving high-quality development through collaboration with global healthcare professionals [5]